JP2019535831A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535831A5
JP2019535831A5 JP2019547600A JP2019547600A JP2019535831A5 JP 2019535831 A5 JP2019535831 A5 JP 2019535831A5 JP 2019547600 A JP2019547600 A JP 2019547600A JP 2019547600 A JP2019547600 A JP 2019547600A JP 2019535831 A5 JP2019535831 A5 JP 2019535831A5
Authority
JP
Japan
Prior art keywords
phosphorus
nitrogen
sulfur
oxygen
silicon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547600A
Other languages
English (en)
Japanese (ja)
Other versions
JP7296882B2 (ja
JP2019535831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062996 external-priority patent/WO2018098264A1/en
Publication of JP2019535831A publication Critical patent/JP2019535831A/ja
Publication of JP2019535831A5 publication Critical patent/JP2019535831A5/ja
Priority to JP2023026999A priority Critical patent/JP2023062180A/ja
Application granted granted Critical
Publication of JP7296882B2 publication Critical patent/JP7296882B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547600A 2016-11-23 2017-11-22 ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法 Active JP7296882B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023026999A JP2023062180A (ja) 2016-11-23 2023-02-24 ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662426079P 2016-11-23 2016-11-23
US62/426,079 2016-11-23
PCT/US2017/062996 WO2018098264A1 (en) 2016-11-23 2017-11-22 Compositions and methods for phosphoramidite and oligonucleotide synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023026999A Division JP2023062180A (ja) 2016-11-23 2023-02-24 ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019535831A JP2019535831A (ja) 2019-12-12
JP2019535831A5 true JP2019535831A5 (enExample) 2021-01-07
JP7296882B2 JP7296882B2 (ja) 2023-06-23

Family

ID=62195630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547600A Active JP7296882B2 (ja) 2016-11-23 2017-11-22 ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
JP2023026999A Pending JP2023062180A (ja) 2016-11-23 2023-02-24 ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023026999A Pending JP2023062180A (ja) 2016-11-23 2023-02-24 ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法

Country Status (6)

Country Link
US (2) US11873316B2 (enExample)
EP (1) EP3544987A4 (enExample)
JP (2) JP7296882B2 (enExample)
CN (1) CN110088113A (enExample)
MA (1) MA46905A (enExample)
WO (1) WO2018098264A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN108137492B (zh) 2015-10-09 2021-12-21 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2017160741A1 (en) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN109562122A (zh) 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
JP7074345B2 (ja) 2016-06-22 2022-05-24 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 一本鎖ｒｎａ編集オリゴヌクレオチド
CA3035293A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
JP7557941B2 (ja) 2017-06-02 2024-09-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
JP7422068B2 (ja) 2017-08-08 2024-01-25 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド組成物及びその方法
US11608355B2 (en) 2017-09-18 2023-03-21 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
TWI844541B (zh) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 寡核苷酸組成物及其使用方法
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
EP4153747A2 (en) 2020-05-22 2023-03-29 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
CA3262119A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii Bv OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND THEIR USE
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
TW202435897A (zh) 2022-11-24 2024-09-16 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ 用於治療遺傳性ｈｆｅ血色沉著病之反義寡核苷酸
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
AU2024246572A1 (en) 2023-03-27 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329892A1 (de) * 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
WO1989009780A1 (en) * 1988-04-15 1989-10-19 Chemical Industry Institute Of Toxicology Site-specific tritium-labeled oligodeoxynucleotides
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
DE69412704T2 (de) 1993-06-10 1999-02-04 Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo Spritzgiessform
US6180766B1 (en) 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
US5571937A (en) 1994-05-13 1996-11-05 Sloan-Kettering Institute For Cancer Research Complementary DNA and toxins
WO1997009443A1 (en) 1995-09-05 1997-03-13 Michigan State University PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5869696A (en) 1996-04-22 1999-02-09 Beckman Instruments, Inc. Universal solid supports and methods for their use
GB9621522D0 (en) * 1996-10-16 1996-12-04 Biocompatibles Ltd Synthesis of phosphorus compounds
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US20030017451A1 (en) * 2000-12-21 2003-01-23 Hui Wang Methods for detecting transcripts
US7153954B2 (en) * 2001-07-12 2006-12-26 Santaris Pharma A/S Method for preparation of LNA phosphoramidites
CA2458393A1 (en) 2001-08-24 2003-03-06 Massachusetts Institute Of Technology Reagents that facilitate the purification of compounds synthesized on a solid support
JP4348044B2 (ja) 2002-02-12 2009-10-21 株式会社キラルジェン 立体規則性の高いジヌクレオシドホスホロチオエートの製造法
US7057062B2 (en) 2002-04-11 2006-06-06 Isis Pharmaceuticals, Inc. Process for manufacturing purified phosphorodiamidite
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
GB0229423D0 (en) * 2002-12-18 2003-01-22 Avecia Ltd Process
JP2005089441A (ja) 2003-08-08 2005-04-07 Toudai Tlo Ltd 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
WO2005023828A1 (ja) 2003-09-02 2005-03-17 Takeshi Wada リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
JP4616175B2 (ja) 2003-09-02 2011-01-19 株式会社キラルジェン ５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
JP4945129B2 (ja) 2004-01-27 2012-06-06 株式会社キラルジェン フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005085272A1 (ja) 2004-03-05 2005-09-15 Takeshi Wada ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
JP4865544B2 (ja) 2004-03-25 2012-02-01 株式会社キラルジェン 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
CA2561741C (en) 2004-04-05 2016-09-27 Alnylam Pharmaceuticals, Inc. Processes and reagents for oligonucleotide synthesis and purification
JP2006292394A (ja) 2005-04-06 2006-10-26 Hiroyuki Yamane シリカゲルの再生方法
WO2006116476A1 (en) * 2005-04-27 2006-11-02 Sigma-Aldrich Co. Activators for oligonucleotide and phosphoramidite synthesis
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP4713514B2 (ja) * 2006-02-20 2011-06-29 エフ．ホフマン−ラ ロシュ アーゲー 改善された標識試薬
WO2009143369A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Method of preparing nucleosides and analogs thereof without using chromatography
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
WO2011034072A1 (ja) 2009-09-16 2011-03-24 株式会社キラルジェン Rna及びその誘導体合成のための新規保護基
JP2011121881A (ja) 2009-12-09 2011-06-23 Nippon Shinyaku Co Ltd ホスホロアミダイト化合物の製造法
JP5847700B2 (ja) 2010-03-05 2016-01-27 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リボヌクレオシドホスホロチオエートの製造方法
JP2011184318A (ja) 2010-03-05 2011-09-22 Univ Of Tokyo リボヌクレシドｈ−ボラノホスホネート
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
EP2647644B1 (en) 2010-11-30 2020-09-09 Wave Life Sciences Japan, Inc. 2'-o-modified rna
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
CN102516337B (zh) 2011-11-02 2014-07-02 东南大学 3’硫代-2’脱氧核糖-3’硝基吡咯亚磷酰胺单体及其合成方法和应用
CN102675386B (zh) 2011-12-24 2014-07-02 河南科技大学 一种龙胆苦苷分离提纯方法
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
JP2015119116A (ja) * 2013-12-19 2015-06-25 株式会社東芝 半導体装置
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
CN103819501B (zh) 2014-03-19 2015-11-04 厦门大学 一种甲基丙烯基亚磷酰胺单体及其合成方法
EP3137478B1 (en) 2014-04-30 2021-09-22 Agilent Technologies, Inc. Phosphorous protecting groups and methods of preparation and use thereof
US20180112217A1 (en) * 2014-11-19 2018-04-26 Roche Innovation Center Copenhagen A/S Stereospecific Phosphorothioate LNA
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN108137492B (zh) 2015-10-09 2021-12-21 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2017160741A1 (en) * 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
US11267843B2 (en) 2016-03-18 2022-03-08 Roche Innovation Center Copenhagen A/S Stereodefining L-monomers
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA45290A (fr) 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
CN109562122A (zh) 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
JP7557941B2 (ja) 2017-06-02 2024-09-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
EP3630788A4 (en) 2017-06-02 2021-04-28 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
JP7492829B2 (ja) 2017-06-28 2024-05-30 ロシュ イノベーション センター コペンハーゲン エーエス 多重カップリングおよび酸化の方法
JP7422068B2 (ja) 2017-08-08 2024-01-25 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド組成物及びその方法
US11608355B2 (en) 2017-09-18 2023-03-21 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
CN112004928A (zh) 2018-04-12 2020-11-27 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
TWI844541B (zh) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 寡核苷酸組成物及其使用方法
JP2022513719A (ja) 2018-12-06 2022-02-09 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法
MA54875A (fr) 2019-02-01 2021-12-08 Wave Life Sciences Ltd Compositions oligonucléotidiques et procédés associés
CA3134036A1 (en) 2019-03-20 2020-09-24 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
WO2020196662A1 (ja) 2019-03-25 2020-10-01 国立大学法人東京医科歯科大学 二本鎖核酸複合体及びその使用
BR112021021203A2 (pt) 2019-04-25 2022-01-04 Wave Life Sciences Ltd Oligonucleotídeo; composição de oligonucleotídeo quiralmente controlada; composição farmacêutica; método para prevenir, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a e/ou prevenir, atrasar o início, desenvolvimento e/ou progresso, e/ou tratar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para aumentar o nível de salto de um éxon prejudicial em uma transcrição de gene ush2a ou seu produto de gene em uma célula; método para prevenir, atrasar o início ou progressão de, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para saltar um éxon prejudicial 13 em um alelo de ush2a em um indivíduo; método para produzir ou aumentar o nível de um éxon de proteína ush2a com salto 13 em um sistema; e composto, oligonucleotídeo, composição ou método
AU2020262485A1 (en) 2019-04-25 2021-11-11 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US20220145300A1 (en) 2019-05-09 2022-05-12 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2021071788A2 (en) 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2021071858A1 (en) 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US20230295619A1 (en) 2020-03-01 2023-09-21 Abbie Madeline Maguire Oligonucleotide compositions and methods thereof
EP4153604A4 (en) 2020-05-22 2024-11-27 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
EP4153747A2 (en) 2020-05-22 2023-03-29 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
WO2022046667A1 (en) 2020-08-24 2022-03-03 Wave Life Sciences Ltd. Cells and non-human animals engineered to express adar1 and uses thereof
WO2022046723A1 (en) 2020-08-24 2022-03-03 Wave Life Sciences Ltd. Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
WO2022067023A1 (en) 2020-09-24 2022-03-31 Mayo Foundation For Medical Education And Research Screening platforms
EP4240849A1 (en) 2020-11-08 2023-09-13 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN116507724A (zh) 2020-11-08 2023-07-28 波涛生命科学有限公司 寡核苷酸组合物及其方法
JP2024536088A (ja) 2021-09-26 2024-10-04 ウェイブ ライフ サイエンシズ リミテッド Ｍｅｃｐ２転写物を編集するための組成物及びその方法
CA3232070A1 (en) 2021-09-26 2023-03-30 Prashant MONIAN Oligonucleotide compositions and methods thereof
WO2023075766A1 (en) 2021-10-27 2023-05-04 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2023076352A2 (en) 2021-10-27 2023-05-04 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP2025506484A (ja) 2022-02-11 2025-03-11 ウェイブ ライフ サイエンシズ リミテッド キラル化合物の立体選択的技術
CN119137134A (zh) 2022-03-02 2024-12-13 波涛生命科学有限公司 寡核苷酸组合物及其用于外显子跳跃的方法
JP2025513847A (ja) 2022-04-15 2025-04-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びそれに関連する方法
WO2023220440A1 (en) 2022-05-12 2023-11-16 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
JP2025526712A (ja) 2022-08-11 2025-08-15 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法
WO2025030155A1 (en) 2023-08-03 2025-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Similar Documents

Publication Publication Date Title
JP2019535831A5 (enExample)
JP6634135B2 (ja) ハリコンドリンｂ類縁体の合成に有用な方法
KR101086678B1 (ko) 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법
KR102634720B1 (ko) 벤조디아제핀-2-온 및 벤조아제핀-2-온 유도체의 분할 방법
JP6673211B2 (ja) モルフォリノオリゴヌクレオチドの製造方法
CN108738321A (zh) GalNAc簇亚磷酰胺
EP2327708A2 (en) Purification method for adefovir dipivoxil
ES2879294T3 (es) Formas polimórficas de Belinostat y procesos para la preparación de las mismas
KR20160095161A (ko) 포스파티딜이노시톨 3-키나제 억제제의 가공 방법
JP2017522343A (ja) ホスホルアミデート類の合成
KR101888392B1 (ko) 트리요오드화된 조영제의 제조
CN107021985A (zh) 药物中间体r‑9‑[2‑(二乙氧基膦酰甲氧基)丙基]腺嘌呤的合成方法
WO2019189867A1 (ja) ビスイミノビオチン化合物の薬物送達用の用途
KR20170018822A (ko) 로바플라틴 결정, 제조 방법 및 약제학적 적용
CN108794517B (zh) 一种精氨酸酶抑制剂及其制备方法与用途
ES2938053T3 (es) Nuevo procedimiento de preparación de enzalutamida
KR101871567B1 (ko) 베타-아미노-다이싸이오에스터 화합물의 제조방법 및 이에 의해 제조된 베타-아미노-다이싸이오에스터 화합물
WO2012041015A1 (zh) 一种非环核苷类抗病毒药物磷酸单酯化合物的制备方法
TW201718510A (zh) 製備1-甲基-3-(三氟甲基)-1h-吡唑-5-醇的方法
US4633014A (en) Substituted 3-hydrazinopropionates
KR102360512B1 (ko) 카바페넴 항생물질의 제조 방법
JP2007028993A (ja) オリゴヌクレオチドプローブ
CA3016253A1 (en) Sulfamate derivative compounds, processes for preparing them and their uses
JP2012240959A (ja) 光学活性β−アミノチオールまたは光学活性β−アミノスルホン酸誘導体の合成法
BR112018006850B1 (pt) Forma cristalina a de composto e processos para preparação da mesma